Please wait...
Comparative study of caregiver burden among the caregivers of psychosis and mood disorder patients attending a rural tertiary teaching hospital
PES Institute of Medical Sciences and Research
India
Biography
DISCOVER
Speakers
Characteristic linguistic styles in young Arabic speaking children diagnosed with ASD
Alyn Hospital
Israel
Speakers
Investigating the cellular mechanisms underpinning the role of leptin and ghrelin and their receptors on hippocampal neurons
University of St Andrews
United Kingdom
Speakers
NRS-2002 scale impact on nutritional status screening of patients with acute cerebrovascular accident
Sechenov University
Russian Federation
Speakers
miRNA expression changes in PD blood leukocytes
UCL
UK
Patheti Venkata Satya Siva Arun presents at the Healthcore Bridge International Medical Conference 2026 — October 16, 2026, Hall B — Infectious Diseases & Immunology, Level 2.
FAQs
Prof. Tanaka will deliver an invited lecture titled 'Alzheimer's Therapeutics 2026: Translating Lecanemab Data to Clinical Reality' in the Neuroscience & Neurology track on Day 2. The presentation features 36-month real-world data from Japan and previews the next wave of anti-amyloid and anti-tau therapies.
Prof. Tanaka served as Asia-Pacific Principal Investigator for the CLARITY-AD Phase III trial of lecanemab. His team enrolled 342 participants across 18 sites in Japan and Korea, and biomarker data from his laboratory directly informed the patient selection criteria incorporated into approved prescribing guidance in Japan and the EU.
Prof. Tanaka's research supports blood-based p-tau217 as the primary screening and monitoring biomarker for anti-amyloid therapy. He also advocates for tau PET imaging at key decision points — particularly before treatment initiation and at 12 months — based on data from the CLARITY-J real-world registry.
Yes. Prof. Tanaka is Principal Investigator for two Phase III trials: one examining anti-tau monotherapy in early Alzheimer's, and one evaluating a dual anti-amyloid/anti-tau combination regimen. Both are currently enrolling across Japan, South Korea, and Singapore.
© 2026 Healthcore Bridge. All rights reserved. Advancing global healthcare through collaboration & innovation.